The Pivotal Study is Aimed to Support a Marketing Authorization Application Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary
Can-Fite BioPharma (CANF) Reports FY22, Provides Clinical Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
PETACH TIKVA, Israel (BUSINESS WIRE) Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory
Can-Fite BioPharma (NYSE:CANF) CEO Pnina Fishman speaks to Proactive s Thomas Warner about her hopes for two new treatments the company is developing during.
28.12.2022 - Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today provided an update on its clinical program for . Seite 1